Key takeaway
What This Development Means
Japan's Ministry of Health, Labour and Welfare is consulting on a notice that would designate most pharmacy medicines for post-market safety and effectiveness planning under amended Article 68-2 of the Pharmaceuticals and Medical Devices Act. Comments close at midnight on 10 October 2026. The proposed duties are intended to apply from 20 May 2027.
Does The Draft Notice Already Require New Post-Market Plans?
No. The notice is under consultation and the proposed application date is 20 May 2027. Existing pharmacovigilance and marketing authorisation duties continue. Companies should monitor the final notice because its scope or timing may change after comments are considered.
Which Products Would Be Outside The Proposed Designation?
The draft excludes in-vitro diagnostic medicines, products exempted by the Minister under Article 14(1) and medicines manufactured in pharmacies. Marketing authorisation holders should confirm product status against the final Japanese text rather than relying on commercial labels alone.
Source basis: Japan e-Gov public consultation, case 495260182, 11 September 2026
Japan Pharmacy Medicine Post-Market Plans Are Proposed
Japan's Ministry of Health, Labour and Welfare has proposed pharmacy medicine post-market plans under Article 68-2(1) of the Pharmaceuticals and Medical Devices Act. The e-Gov consultation, case 495260182, opened on 11 September 2026 and closes at 00:00 Japan Standard Time on 10 October.
The draft notice would identify medicines for which marketing authorisation holders may need structured post-market safety and effectiveness management. It is proposed, not yet a binding designation. Existing pharmacovigilance and product obligations continue while the Ministry considers comments.
Scope And Planned Safety Management
The proposed designation covers pharmacy medicines, subject to stated exclusions. In-vitro diagnostic medicines, products exempted by the Minister under Article 14(1), and medicines manufactured in pharmacies are outside the proposed notice's scope.
For designated products, marketing authorisation holders would prepare and implement a post-market plan where necessary. The supporting outline describes collection of safety and effectiveness information, investigations or tests, and risk-minimisation measures. The proposal establishes a management framework rather than publishing an ingredient list, impurity threshold or uniform testing frequency.
The draft should be read with the 2025 legislative amendment. Law No. 37 of 2025 created the amended statutory basis, but the notice is the instrument that would define the designated medicine population. That distinction matters because adoption of the parent amendment did not itself make the draft list final.
What Applies Now And Later
Current marketing authorisation, good vigilance practice, safety reporting, labelling and distribution controls remain in place. Companies should not wait for the proposed notice before meeting those duties, and they should not treat the consultation as an immediate requirement to file a new plan.
The Ministry expects to issue the notice in late October 2026, subject to the consultation outcome. Application is proposed for 20 May 2027. Until a final notice is published, both timing and wording remain capable of change.
Marketing authorisation holders should map pharmacy medicines to the proposed exclusions, identify current post-market plans and test whether safety and effectiveness data can be combined into the expected framework. Importers and distributors should confirm information-exchange routes for adverse events, effectiveness signals and corrective measures. Contractual responsibilities should not interrupt the authorisation holder's oversight.
Analysis, clearly identified as an inference: a category-wide designation can create a larger governance task than a list of named active ingredients. Portfolio owners may need a documented reason for the intensity of each plan, including why particular investigations or risk measures are necessary, rather than assuming one standard template fits every pharmacy medicine.
Related Foresight coverage includes Japan's regulatory news archive, Japan's proposed chemical hazard communication duties and Japan's new workplace chemical exposure limits.
Related Articles
Spain Congress Publishes Sweeping Medicines And Health Products Bill
Spain's medicines and health products bill proposes major supply, manufacturing, pricing and enforcement reforms across healthcare products.
EU Water Protection Rules Tighten Controls On PFAS And Pharmaceuticals
Directive (EU) 2026/805 strengthens EU water protection by expanding controls on PFAS, pharmaceuticals, bisphenols and emerging pollutants. The rules increase monitoring expectations, sharpen future quality standards and give ECHA a larger scientific role, creating new compliance considerations across chemicals, manufacturing, water treatment and downstream sectors.
FDA Mandates ICH E2B(R3) Data Standards For Safety Reporting From October 2026
The FDA will require ICH E2B(R3) data standards for electronic safety reporting from October 2026. The change enhances data quality and global harmonisation but requires significant system upgrades. Stakeholders across the pharmaceutical value chain must act early to ensure compliance and avoid regulatory risk.
